The final, formatted version of the article will be published soon.
ORIGINAL RESEARCH article
Front. Oncol.
Sec. Neuro-Oncology and Neurosurgical Oncology
Volume 15 - 2025 |
doi: 10.3389/fonc.2025.1522249
This article is part of the Research Topic Advancements in Meningioma Management: From Imaging Techniques to Personalized Medicine Approaches View all articles
A Novel Compound, SYHA1813, Inhibits Malignant Meningioma Growth Directly by Boosting p53 Pathway Activation and Impairing DNA Repair
Provisionally accepted
Yanjie Lan Shenglan Li 
Wenbin Li * Jiachen Wang Xin Yang Can Wang Mengqian Huang Rong Zhang Feng Chen - Beijing Tiantan Hospital, Capital Medical University, Beijing, China
Meningioma is one of the common tumors of central nervous system; but effective therapies for malignant meningiomas are still lacking. Therefore, developing novel therapeutic reagents is urgently needed. SYHA1813 is a novel compound, our previous study demonstrated its potent anti-tumor activity on glioblastoma through inhibiting macrophages and HUVECs. However, the precise functional role of SYHA1813 in meningiomas remains unclear. Herein, we aimed to investigate the direct tumor-inhibitory effects of SYHA1813 on meningioma both in vitro and in vivo, and explore its potential molecular mechanisms. Our results showed that SYHA1813 suppressed the proliferation, colony formation, migration and invasion of meningioma cells in vitro. Furthermore, we found SYHA1813 induced G2/M cell cycle arrest, apoptosis, and cellular senescence. Mechanistically, RNA-seq revealed that SYHA1813 activated P53 pathway and impaired DNA repair. In vivo, SYHA1813 effectively inhibited the growth of meningioma xenografts in a mouse model. Additionally, in an ongoing first-in-human phase I trial, this patient with recurrent meningioma provided preliminary clinical evidence supporting the anti-tumor activity of SYHA1813. This study unveiled a novel antitumor mechanism of SYHA1813, showing its ability to directly target and kill meningioma cells in vitro and in vivo. Our findings highlighted the promising potential of SYHA1813 as a therapeutic agent for treating malignant meningiomas.
Keywords: Meningioma, SYHA1813, therapy, p53 pathway, DNA repair 31 32
Received: 04 Nov 2024; Accepted: 22 Jan 2025.
Copyright: © 2025 Lan, Li, Li, Wang, Yang, Wang, Huang, Zhang and Chen. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
* Correspondence:
Wenbin Li, Beijing Tiantan Hospital, Capital Medical University, Beijing, China
Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.